Literature DB >> 23891248

Relation of preoperative serum albumin levels to survival in patients undergoing left ventricular assist device implantation.

Tomoko S Kato1, Shuichi Kitada, Jonathan Yang, Christina Wu, Hiroo Takayama, Yoshifumi Naka, Maryjane Farr, Donna M Mancini, P Christian Schulze.   

Abstract

Hypoalbuminemia has been recognized as a prognostic indicator in patients with heart failure. We aimed to investigate the association of hypoalbuminemia with postoperative mortality in patients undergoing left ventricular assist device (LVAD) implantation. We studied 272 consecutive patients undergoing LVAD implantation from 2000 to 2010 at our institution. Preoperative clinical characteristics and laboratory variables associated with mortality were analyzed. Postoperative survival of patients with preoperative hypoalbuminemia (<3.5 g/dl, n = 125) and those with normal albumin concentration (≥3.5 g/dl, n = 147) was compared. Survival after LVAD surgery was better in patients with normal albumin levels compared with those with hypoalbuminemia before surgery (3 and 12 months: 93.2% vs 82.4% and 88.4% vs 75.2%, respectively, p <0.001). Multivariate analysis revealed that preoperative albumin was independently associated with mortality after LVAD implantation (hazard ratio 0.521, 95% confidence interval 0.290 to 0.934; p = 0.029.) Furthermore, the impact of normalization of albumin levels during LVAD support on postoperative survival was analyzed in both groups. Subgroup analysis of patients with preoperative hypoalbuminemia and postoperative normalization of albumin levels (n = 81) showed improved survival compared with those who remained hypoalbuminemia (n = 44) or those who had decreasing albumin levels during LVAD support (n = 40; 3-month survival: 92.6% vs 63.6% and 65.0%; p <0.01). In conclusion, preoperative hypoalbuminemia is associated with poor prognosis after LVAD surgery. Postoperative normalization of albumin level is associated with improved survival. Attention to albumin levels by correcting nutrition, inflammation, and hepatic function could be an effective way to improve prognosis in patients evaluated for LVAD implantation.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23891248      PMCID: PMC4074378          DOI: 10.1016/j.amjcard.2013.06.023

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  30 in total

Review 1.  Nutrition risk factors in older coronary artery bypass graft patients.

Authors:  Rose Ann Dimaria-Ghalili
Journal:  Nutr Clin Pract       Date:  2008 Oct-Nov       Impact factor: 3.080

2.  Improved survival and decreasing incidence of adverse events with the HeartMate II left ventricular assist device as bridge-to-transplant therapy.

Authors:  Ranjit John; Forum Kamdar; Kenneth Liao; Monica Colvin-Adams; Andrew Boyle; Lyle Joyce
Journal:  Ann Thorac Surg       Date:  2008-10       Impact factor: 4.330

3.  Clinical outcomes in patients with chronic congestive heart failure who undergo left ventricular assist device implantation.

Authors:  Nicholas C Dang; Veli K Topkara; Brian T Kim; Michelle L Mercando; Joy Kay; Yoshifumi Naka
Journal:  J Thorac Cardiovasc Surg       Date:  2005-10-13       Impact factor: 5.209

4.  Left ventricular assist device and drug therapy for the reversal of heart failure.

Authors:  Emma J Birks; Patrick D Tansley; James Hardy; Robert S George; Christopher T Bowles; Margaret Burke; Nicholas R Banner; Asghar Khaghani; Magdi H Yacoub
Journal:  N Engl J Med       Date:  2006-11-02       Impact factor: 91.245

5.  Advanced heart failure treated with continuous-flow left ventricular assist device.

Authors:  Mark S Slaughter; Joseph G Rogers; Carmelo A Milano; Stuart D Russell; John V Conte; David Feldman; Benjamin Sun; Antone J Tatooles; Reynolds M Delgado; James W Long; Thomas C Wozniak; Waqas Ghumman; David J Farrar; O Howard Frazier
Journal:  N Engl J Med       Date:  2009-11-17       Impact factor: 91.245

6.  Acute Physiology and Chronic Health Evaluation (APACHE) IV: hospital mortality assessment for today's critically ill patients.

Authors:  Jack E Zimmerman; Andrew A Kramer; Douglas S McNair; Fern M Malila
Journal:  Crit Care Med       Date:  2006-05       Impact factor: 7.598

7.  Albumin levels predict survival in patients with systolic heart failure.

Authors:  Tamara B Horwich; Kamyar Kalantar-Zadeh; Robb W MacLellan; Gregg C Fonarow
Journal:  Am Heart J       Date:  2008-01-30       Impact factor: 4.749

Review 8.  Cardiac cachexia: a systematic overview.

Authors:  Stephan von Haehling; Mitja Lainscak; Jochen Springer; Stefan D Anker
Journal:  Pharmacol Ther       Date:  2008-11-14       Impact factor: 12.310

9.  Outcomes of left ventricular assist device implantation as destination therapy in the post-REMATCH era: implications for patient selection.

Authors:  Katherine Lietz; James W Long; Abdallah G Kfoury; Mark S Slaughter; Marc A Silver; Carmelo A Milano; Joseph G Rogers; Yoshifumi Naka; Donna Mancini; Leslie W Miller
Journal:  Circulation       Date:  2007-07-16       Impact factor: 29.690

10.  Liver function abnormalities and outcome in patients with chronic heart failure: data from the Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) program.

Authors:  Larry A Allen; G Michael Felker; Stuart Pocock; John J V McMurray; Marc A Pfeffer; Karl Swedberg; Duolao Wang; Salim Yusuf; Eric L Michelson; Christopher B Granger
Journal:  Eur J Heart Fail       Date:  2009-02       Impact factor: 15.534

View more
  8 in total

1.  Post-transplant survival estimation using pre-operative albumin levels.

Authors:  Tomoko S Kato; Matthew Lippel; Yoshifumi Naka; Donna M Mancini; P Christian Schulze
Journal:  J Heart Lung Transplant       Date:  2014-02-04       Impact factor: 10.247

2.  Sex Differences in Mortality Based on United Network for Organ Sharing Status While Awaiting Heart Transplantation.

Authors:  Eileen M Hsich; Eugene H Blackstone; Lucy Thuita; Dennis M McNamara; Joseph G Rogers; Hemant Ishwaran; Jesse D Schold
Journal:  Circ Heart Fail       Date:  2017-06       Impact factor: 8.790

3.  Readmission due to driveline infection can be predicted by new score by using serum albumin and body mass index during long-term left ventricular assist device support.

Authors:  Teruhiko Imamura; Koichiro Kinugawa; Daisuke Nitta; Toshiro Inaba; Hisataka Maki; Masaru Hatano; Osamu Kinoshita; Kan Nawata; Shunei Kyo; Minoru Ono
Journal:  J Artif Organs       Date:  2015-01-21       Impact factor: 1.731

4.  Variables of importance in the Scientific Registry of Transplant Recipients database predictive of heart transplant waitlist mortality.

Authors:  Eileen M Hsich; Lucy Thuita; Dennis M McNamara; Joseph G Rogers; Maryam Valapour; Lee R Goldberg; Clyde W Yancy; Eugene H Blackstone; Hemant Ishwaran
Journal:  Am J Transplant       Date:  2019-02-13       Impact factor: 8.086

5.  Comparison of early versus delayed timing of left ventricular assist device implantation as a bridge-to-transplantation: An analysis of the UNOS dataset.

Authors:  Shuichi Kitada; P Christian Schulze; Zhezhen Jin; Kevin Clerkin; Shunichi Homma; Donna M Mancini
Journal:  Int J Cardiol       Date:  2015-11-09       Impact factor: 4.164

6.  Laparoscopic versus open ventral hernia repair in patients with chronic liver disease.

Authors:  Yen-Yi Juo; Matthew Skancke; Jeremy Holzmacher; Richard L Amdur; Paul P Lin; Khashayar Vaziri
Journal:  Surg Endosc       Date:  2016-06-22       Impact factor: 4.584

7.  Renal Function and Outcomes With Use of Left Ventricular Assist Device Implantation and Inotropes in End-Stage Heart Failure: A Retrospective Single Center Study.

Authors:  Sean Verma; Emmanuel Bassily; Shane Leighton; Rahul Mhaskar; Igor Sunjic; Angel Martin; Nancy Rihana; Tambi Jarmi; Claude Bassil
Journal:  J Clin Med Res       Date:  2017-05-22

8.  Prognostic role of albumin level in heart failure: A systematic review and meta-analysis.

Authors:  Mahmoud El Iskandarani; Bara El Kurdi; Ghulam Murtaza; Timir K Paul; Marwan M Refaat
Journal:  Medicine (Baltimore)       Date:  2021-03-12       Impact factor: 1.817

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.